How Retatrutide Revs Your Metabolism

In today's episode we're diving deep into retatrutide, Eli Lilly's experimental "Triple G" peptide that is reshaping metabolic medicine.

We examine how this investigational triple-hormone receptor agonist targets GLP-1, GIP, and glucagon receptors simultaneously—not only curbing appetite like older treatments, but actively increasing resting energy expenditure to burn more calories. We review the latest clinical evidence, including pivotal Phase 3 TRIUMPH trial results where participants lost up to an average of 28.3% of their body weight over 80 weeks on the maximum 12 mg dose.

We also break down the full safety profile, covering common gastrointestinal symptoms like nausea and vomiting, as well as unique sensory side effects such as dysesthesia.

Finally, we explore recommended dose titration protocols to minimize adverse events, potential improvements in liver and cardiorenal health markers, and how patients can safely access retatrutide exclusively through legitimate clinical trials.

=== REFERENCES ===

• https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html
• https://meto.co/blog/how-to-get-retatrutide
• https://en.wikipedia.org/wiki/Retatrutide
• https://ro.co/weight-loss/retatrutide-dosing/
• https://lolahealth.com/blogs/longevity/retatrutide-side-effects
• https://my-bmi.ie/
• https://www.retaweightloss.com/article/retatrutide-approval-status-2026-monthly-update
• https://doi.org/10.53301/lw/197354
• https://doi.org/10.7570/jomes26005

Become a supporter of this podcast: https://www.spreaker.com/podcast/foodnourish-deep-dives--6602003/support.

🤗 Support the show: Become a supporter for just 2€ per month to remove advertisements and help us continue bringing interesting topics while confronting mainstream narratives on health.

Support FoodNourish Deep Dives

This episode includes AI-generated content.